Q2 2024 EPS Estimates for Hims & Hers Health, Inc. (NYSE:HIMS) Lifted by Analyst

Hims & Hers Health, Inc. (NYSE:HIMS) – Stock analysts at Seaport Res Ptn lifted their Q2 2024 earnings per share (EPS) estimates for Hims & Hers Health in a report issued on Monday, May 6th. Seaport Res Ptn analyst A. Kessler now forecasts that the company will post earnings of $0.05 per share for the quarter, up from their prior estimate of $0.02. Seaport Res Ptn currently has a “Buy” rating on the stock. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.11 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s FY2024 earnings at $0.19 EPS and FY2025 earnings at $0.37 EPS.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The company had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The firm’s quarterly revenue was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.05) EPS.

Several other research firms have also recently issued reports on HIMS. Jefferies Financial Group reiterated a “hold” rating and issued a $15.00 price objective (down from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Canaccord Genuity Group initiated coverage on Hims & Hers Health in a research report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target on the stock. Canaccord Genuity Group started coverage on Hims & Hers Health in a report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price objective for the company. Leerink Partnrs reissued a “market perform” rating on shares of Hims & Hers Health in a report on Monday, February 26th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $14.00 to $16.00 and gave the stock a “hold” rating in a report on Tuesday. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.07.

Hims & Hers Health Stock Up 6.1 %

Shares of HIMS opened at $12.36 on Wednesday. The firm has a market capitalization of $2.65 billion, a PE ratio of -112.36 and a beta of 0.97. The firm has a 50-day moving average price of $14.04 and a 200 day moving average price of $10.35. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $17.16.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently made changes to their positions in the company. Forerunner Ventures Management LLC acquired a new position in Hims & Hers Health in the fourth quarter worth approximately $86,836,000. Vanguard Group Inc. increased its stake in shares of Hims & Hers Health by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after purchasing an additional 428,671 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Hims & Hers Health by 39.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,272,750 shares of the company’s stock valued at $8,006,000 after purchasing an additional 357,590 shares in the last quarter. Federated Hermes Inc. lifted its stake in shares of Hims & Hers Health by 38.6% in the 3rd quarter. Federated Hermes Inc. now owns 1,032,452 shares of the company’s stock valued at $6,494,000 after purchasing an additional 287,552 shares during the last quarter. Finally, Must Asset Management Inc. acquired a new position in Hims & Hers Health during the third quarter worth $1,596,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Hims & Hers Health news, insider Soleil Boughton sold 4,080 shares of the firm’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40. Following the completion of the sale, the insider now directly owns 154,345 shares in the company, valued at approximately $1,548,080.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Hims & Hers Health news, insider Soleil Boughton sold 4,080 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $10.03, for a total value of $40,922.40. Following the completion of the sale, the insider now owns 154,345 shares in the company, valued at approximately $1,548,080.35. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $14.97, for a total transaction of $2,827,653.36. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 736,191 shares of company stock worth $9,733,700. 31.63% of the stock is owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.